Mason Michael's Form 4 filing
Karyopharm Therapeutics Inc. (KPTI) · filed Mar 2, 2022
- Accession no.
- 0001209191-22-014628
- Filed
- Mar 2, 2022
- Trade date
- Feb 28, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $24.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mason MichaelCIK 0001514291 | Officer (EVP, CFO & Treasurer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 28, 2022 | Common Stock | AGrant or awardAcquired | +88,200 | $0.00 | $0 | 141,508 | Direct | |
| Feb 28, 2022 | Common Stock | SSaleDisposed | −2,398 | $10.24F3 | −$24,555.52 | 139,110 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 28, 2022 | Common Stock | AGrant or awardAcquired | +111,600 | $0.00 | $0 | 111,600 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.24 to $10.35, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.